Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target ...
Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price targe...
RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $147 price target.
Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price targe...
Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectatio...
Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical devices.
Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the sto...
